Facilitating Innovative Nuclear Diagnostics Act of 2023
Latest Action
Forwarded by Subcommittee to Full Committee by Voice Vote.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Facilitating Innovative Nuclear Diagnostics Act of 2023 (H.R. 1199) is a health policy bill introduced in the 118th Congress aimed at advancing nuclear diagnostic technologies. The bill's specific provisions and text are not publicly available, but it has been considered by a House subcommittee and forwarded to the full committee by voice vote. The bill is currently classified as failed or expired, indicating it did not become law during the 118th Congress.
H.R. 1199 sought to promote innovation in nuclear diagnostic methods within the health sector but did not pass before the end of the 118th Congress.
- The bill focuses on facilitating advancements in nuclear diagnostics, a subset of health technology.
- It was introduced and considered in the House of Representatives during the 118th Congress.
- The latest procedural action was a voice vote forwarding the bill from a subcommittee to the full committee.
- The bill ultimately failed or expired without enactment.
['Healthcare providers specializing in nuclear diagnostics', 'Medical technology developers and researchers in nuclear medicine', 'Patients who may benefit from improved diagnostic technologies', 'Relevant federal health agencies involved in medical technology oversight']
['Lack of publicly available bill text limits understanding of specific implementation mechanisms and funding sources.', 'Without enacted law, no formal authority or regulatory changes were established.', 'Potential costs and oversight responsibilities related to promoting innovative nuclear diagnostics are unknown.', 'The failure to pass may delay potential advancements in nuclear diagnostic technologies.']
The bill was introduced and considered during the 118th Congress in the House of Representatives. It progressed through a subcommittee by voice vote but did not advance to become law before the congressional session ended, resulting in its failed or expired status. No further legislative actions are recorded.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential delay in adoption or development of innovative nuclear diagnostic technologies due to lack of legislative support.', 'Possible missed opportunities for federal agencies to coordinate or fund nuclear diagnostic advancements.', 'Healthcare sector may continue relying on existing diagnostic methods without legislative incentives for innovation.']
The absence of the bill's full text and official summary limits the ability to fully assess the scope, funding, and regulatory impact of H.R. 1199. Transparency is constrained as the bill did not advance beyond committee consideration and ultimately expired. Future tracking of similar legislation would benefit from more complete documentation to enable thorough public and expert review.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.